Cargando…
Parkinson’s disease, dopaminergic drugs and the plant world
A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson’s disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neur...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483127/ https://www.ncbi.nlm.nih.gov/pubmed/36133818 http://dx.doi.org/10.3389/fphar.2022.970714 |
_version_ | 1784791607281713152 |
---|---|
author | Kempster, Peter Ma, Andrew |
author_facet | Kempster, Peter Ma, Andrew |
author_sort | Kempster, Peter |
collection | PubMed |
description | A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson’s disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neurochemistry of the basal ganglia came from the study of phytochemicals. This article narrates the development of pharmacotherapy for PD in terms of historically important plant-derived substances—tropane and hamala alkaloids, reserpine, levodopa, apomorphine, and ergoline dopamine receptor agonists. Alkaloids are nitrogen-containing secondary metabolic products that tend to be biologically active. They appear to be involved in plants’ adaptation to herbivorous animals, though their exact purpose and the ways in which they work are uncertain. A sizable group of alkaloids influence animal dopaminergic systems, highlighting a key biological relationship. While animals must acquire the energy that plants harness, plants need to engage with the animal attribute that they lack—movement—in order to maximize their reproductive fitness. Neuroactive flowering plant compounds have been interacting with vertebrate and invertebrate motor systems for 100 million years. A deep evolutionary connection helps to explain why the pharmacological treatment of PD is imprinted with the power of these mysterious botanical chemicals. |
format | Online Article Text |
id | pubmed-9483127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94831272022-09-20 Parkinson’s disease, dopaminergic drugs and the plant world Kempster, Peter Ma, Andrew Front Pharmacol Pharmacology A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson’s disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neurochemistry of the basal ganglia came from the study of phytochemicals. This article narrates the development of pharmacotherapy for PD in terms of historically important plant-derived substances—tropane and hamala alkaloids, reserpine, levodopa, apomorphine, and ergoline dopamine receptor agonists. Alkaloids are nitrogen-containing secondary metabolic products that tend to be biologically active. They appear to be involved in plants’ adaptation to herbivorous animals, though their exact purpose and the ways in which they work are uncertain. A sizable group of alkaloids influence animal dopaminergic systems, highlighting a key biological relationship. While animals must acquire the energy that plants harness, plants need to engage with the animal attribute that they lack—movement—in order to maximize their reproductive fitness. Neuroactive flowering plant compounds have been interacting with vertebrate and invertebrate motor systems for 100 million years. A deep evolutionary connection helps to explain why the pharmacological treatment of PD is imprinted with the power of these mysterious botanical chemicals. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9483127/ /pubmed/36133818 http://dx.doi.org/10.3389/fphar.2022.970714 Text en Copyright © 2022 Kempster and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Kempster, Peter Ma, Andrew Parkinson’s disease, dopaminergic drugs and the plant world |
title | Parkinson’s disease, dopaminergic drugs and the plant world |
title_full | Parkinson’s disease, dopaminergic drugs and the plant world |
title_fullStr | Parkinson’s disease, dopaminergic drugs and the plant world |
title_full_unstemmed | Parkinson’s disease, dopaminergic drugs and the plant world |
title_short | Parkinson’s disease, dopaminergic drugs and the plant world |
title_sort | parkinson’s disease, dopaminergic drugs and the plant world |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483127/ https://www.ncbi.nlm.nih.gov/pubmed/36133818 http://dx.doi.org/10.3389/fphar.2022.970714 |
work_keys_str_mv | AT kempsterpeter parkinsonsdiseasedopaminergicdrugsandtheplantworld AT maandrew parkinsonsdiseasedopaminergicdrugsandtheplantworld |